Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

NCT07092410 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The study was terminated early due to insufficient patient recruitment.

Conditions

Melanoma BRAF V600E/K Mutated

Interventions

DRUG: Encorafenib & Binimetinib Treatment

Sponsor

SRH Wald-Klinikum Gera GmbH

Collaborators

[object Object]